216 related articles for article (PubMed ID: 37923771)
1. Regulation of eDHFR-tagged proteins with trimethoprim PROTACs.
Etersque JM; Lee IK; Sharma N; Xu K; Ruff A; Northrup JD; Sarkar S; Nguyen T; Lauman R; Burslem GM; Sellmyer MA
Nat Commun; 2023 Nov; 14(1):7071. PubMed ID: 37923771
[TBL] [Abstract][Full Text] [Related]
2. A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy.
Lee IK; Sharma N; Noguera-Ortega E; Liousia M; Baroja ML; Etersque JM; Pham J; Sarkar S; Carreno BM; Linette GP; Puré E; Albelda SM; Sellmyer MA
Mol Ther; 2023 Dec; 31(12):3564-3578. PubMed ID: 37919903
[TBL] [Abstract][Full Text] [Related]
3. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
[TBL] [Abstract][Full Text] [Related]
4. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
5. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
7. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
8. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
9. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
10. Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene.
Sellmyer MA; Richman SA; Lohith K; Hou C; Weng CC; Mach RH; O'Connor RS; Milone MC; Farwell MD
Mol Ther; 2020 Jan; 28(1):42-51. PubMed ID: 31668558
[TBL] [Abstract][Full Text] [Related]
11. PROTACS: A technology with a gold rush-like atmosphere.
Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
[TBL] [Abstract][Full Text] [Related]
12. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
13. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
Yao R; Luo T; Wang M
Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
[TBL] [Abstract][Full Text] [Related]
14. Target protein localization and its impact on PROTAC-mediated degradation.
Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
[TBL] [Abstract][Full Text] [Related]
15. Chemical Dimerization-Induced Protein Condensates on Telomeres.
Zhao R; Chenoweth DM; Zhang H
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33900288
[TBL] [Abstract][Full Text] [Related]
16. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
[TBL] [Abstract][Full Text] [Related]
17. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
[TBL] [Abstract][Full Text] [Related]
19. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
20. An in vivo covalent TMP-tag based on proximity-induced reactivity.
Gallagher SS; Sable JE; Sheetz MP; Cornish VW
ACS Chem Biol; 2009 Jul; 4(7):547-56. PubMed ID: 19492849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]